- Home
- CORT vs BPMC Comparison
CORT vs BPMC Comparison
Compare CORT & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CORT
- BPMC
- Stock Information
- Founded
- CORT 1998
- BPMC 2008
- Country
- CORT United States
- BPMC United States
- Employees
- CORT N/A
- BPMC N/A
- Industry
- CORT Biotechnology: Pharmaceutical Preparations
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- CORT Health Care
- BPMC Health Care
- Exchange
- CORT Nasdaq
- BPMC Nasdaq
- Market Cap
- CORT 7.1B
- BPMC 7.0B
- IPO Year
- CORT N/A
- BPMC 2015
- Fundamental
- Price
- CORT $63.54
- BPMC $92.25
- Analyst Decision
- CORT Strong Buy
- BPMC Buy
- Analyst Count
- CORT 4
- BPMC 19
- Target Price
- CORT $97.00
- BPMC $123.61
- AVG Volume (30 Days)
- CORT 894.6K
- BPMC 1.0M
- Earning Date
- CORT 02-26-2025
- BPMC 02-13-2025
- Dividend Yield
- CORT N/A
- BPMC N/A
- EPS Growth
- CORT 57.97
- BPMC N/A
- EPS
- CORT 1.26
- BPMC N/A
- Revenue
- CORT $628,555,000.00
- BPMC $508,824,000.00
- Revenue This Year
- CORT $46.47
- BPMC $44.29
- Revenue Next Year
- CORT $21.49
- BPMC $32.49
- P/E Ratio
- CORT $50.40
- BPMC N/A
- Revenue Growth
- CORT 39.67
- BPMC 104.04
- 52 Week Low
- CORT $20.84
- BPMC $80.68
- 52 Week High
- CORT $75.00
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- CORT 46.90
- BPMC 34.05
- Support Level
- CORT $71.50
- BPMC $90.84
- Resistance Level
- CORT $75.00
- BPMC $96.78
- Average True Range (ATR)
- CORT 3.33
- BPMC 4.34
- MACD
- CORT -0.74
- BPMC -2.26
- Stochastic Oscillator
- CORT 3.00
- BPMC 5.64
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.